Treatment considerations for patients with advanced squamous cell carcinoma of the lung: a plain language summary.

Pub Date : 2022-09-01 DOI:10.2217/lmt-2022-0017
Edgardo S Santos, Estelamari Rodriguez
{"title":"Treatment considerations for patients with advanced squamous cell carcinoma of the lung: a plain language summary.","authors":"Edgardo S Santos,&nbsp;Estelamari Rodriguez","doi":"10.2217/lmt-2022-0017","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this article about?: </strong>This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung.</p><p><strong>What is scc of the lung?: </strong>SCC of the lung is a type of non-small-cell lung cancer (NSCLC for short) that is usually linked with smoking. It can be difficult to treat because it is often diagnosed after it has spread to other parts of the body.</p><p><strong>What first-line treatment options are available for people with scc of the lung?: </strong>Most patients receive a combination of chemotherapy and immunotherapy as their first-line treatment (the first treatment they receive after their diagnosis). Immunotherapy drugs have improved how long people with SCC of the lung can live for. However, for most patients, they eventually stop working. At this point, other second-line treatments are considered, meaning treatments patients receive after their first-line treatment is stopped due to side effects or because it no longer works.</p><p><strong>What second-line treatment options are available to people with scc of the lung?: </strong>Immunotherapy drugs were originally developed as second-line options after chemotherapy. However, immunotherapy drugs are now used with chemotherapies as first-line treatments. This has left a gap for second-line treatment options. There are some drugs available for second-line treatment, such as afatinib, which comes as a tablet, and docetaxel with or without ramucirumab, which is given as an infusion. Other potential treatments are being developed.</p><p><strong>What emerging treatment options are being developed?: </strong>Some early clinical trials of potential treatments have shown promise, but more results are needed. Research into the genetic mutations linked with the development of SCC of the lung is also ongoing. It is hoped that this will help identify patients who might benefit from specific treatments.</p><p><strong>Who should read this article?: </strong>People with SCC of the lung and their caregivers, patient advocates, and healthcare professionals, including those who are helping people learn about scientific discoveries and potential new therapeutic strategies.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/84/lmt-11-56.PMC10241114.pdf","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2022-0017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

What is this article about?: This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung.

What is scc of the lung?: SCC of the lung is a type of non-small-cell lung cancer (NSCLC for short) that is usually linked with smoking. It can be difficult to treat because it is often diagnosed after it has spread to other parts of the body.

What first-line treatment options are available for people with scc of the lung?: Most patients receive a combination of chemotherapy and immunotherapy as their first-line treatment (the first treatment they receive after their diagnosis). Immunotherapy drugs have improved how long people with SCC of the lung can live for. However, for most patients, they eventually stop working. At this point, other second-line treatments are considered, meaning treatments patients receive after their first-line treatment is stopped due to side effects or because it no longer works.

What second-line treatment options are available to people with scc of the lung?: Immunotherapy drugs were originally developed as second-line options after chemotherapy. However, immunotherapy drugs are now used with chemotherapies as first-line treatments. This has left a gap for second-line treatment options. There are some drugs available for second-line treatment, such as afatinib, which comes as a tablet, and docetaxel with or without ramucirumab, which is given as an infusion. Other potential treatments are being developed.

What emerging treatment options are being developed?: Some early clinical trials of potential treatments have shown promise, but more results are needed. Research into the genetic mutations linked with the development of SCC of the lung is also ongoing. It is hoped that this will help identify patients who might benefit from specific treatments.

Who should read this article?: People with SCC of the lung and their caregivers, patient advocates, and healthcare professionals, including those who are helping people learn about scientific discoveries and potential new therapeutic strategies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
晚期肺鳞状细胞癌患者的治疗注意事项:简单的语言总结。
这篇文章是关于什么的?这篇简明扼要的摘要报道了最近一篇综述文章的要点,该文章讨论了一种称为肺鳞状细胞癌(SCC)的癌症的当前治疗方案。什么是肺scc ?肺癌是一种非小细胞肺癌(简称NSCLC),通常与吸烟有关。它很难治疗,因为它通常是在扩散到身体其他部位后才被诊断出来的。对于肺鳞癌患者有哪些一线治疗方案?大多数患者接受化疗和免疫治疗联合作为一线治疗(诊断后接受的第一个治疗)。免疫治疗药物提高了肺细胞癌患者的生存时间。然而,对于大多数患者来说,它们最终会停止工作。在这一点上,考虑其他二线治疗,即患者在一线治疗因副作用或不再有效而停止后接受的治疗。肺细胞癌患者有哪些二线治疗方案?免疫治疗药物最初是作为化疗后的二线选择而开发的。然而,免疫治疗药物现在与化疗一起作为一线治疗。这给二线治疗方案留下了空白。有一些药物可用于二线治疗,如片剂的阿法替尼,以及多西他赛加或不加ramucirumab的输注。其他潜在的治疗方法正在开发中。正在开发哪些新的治疗方案?当前位置一些潜在治疗方法的早期临床试验已经显示出希望,但还需要更多的结果。与肺SCC发展相关的基因突变研究也在进行中。希望这将有助于确定可能从特定治疗中受益的患者。谁应该读这篇文章?:肺鳞状细胞癌患者及其护理人员、患者倡导者和医疗保健专业人员,包括那些帮助人们了解科学发现和潜在新治疗策略的人员。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1